Variables Values [a.sub.0] 2.0 x [10.sup.6] [M] [b.sub.0] 1.0 x [10.sup.6] [M] [c.sub.0] 1.0 x [10.sup.6] [M] [k.sub.1] 2.1 x [10.sup.7] [M.sup.-1][s.sup.-1] [l.sub.1] 0 [M.sup.-1][s.sup.-1] [k.sub.2] 2.74 x [10.sup.6] [M.sup.-1][s.sup.-1] [l.sub.2] 2.0 x [10.sup.-4] [M.sup.-1][s.sup.-1] [k.sub.3] 2.0 x [10.sup.6] [M.sup.-1][s.sup.-1] [l.sub.3] 1.0 x [10.sup.-2] [M.sup.-1][s.sup.-1] FIGURE 2: Binding sites of a (MMP2), b (TIMP2), and c (
MT1MMP).
Rapti et al., "The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (
MT1MMP) in a cell-based environment," Cancer Letters, vol.
The variable ability of tumor cell lines to bind progelatinase A with or without enzyme activation suggests the presence of a progelatinase A receptor distinct from
MT1MMP receptor, such as integrin [alpha]v[beta]3 of the surface of cultured melanoma cells [101].
Therefore, we examined whether VPA stimulates the expression of MMP-2 and
MT1MMP in CB MSC.
Estrogen deficiency induced by ovariectomy gives rise to a reduction of active MMP-2 in the initial phase and a concurrent elevation of MMP-2 and MT1MMP expression in latter period [54].
Bone marrow-derived stem cells (BMSCs) induce an angiogenic effect and elicit vessel morphogenesis both in vitro and in vivo depending on proteolytic ability of MT1MMP [68].